Sept 10 (Reuters) - Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .
Opiant earlier this year was awarded a $7.4 million grant by the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of a nasally-applied version of overdose treatment nalmefene. (Reporting by Noor Zainab Hussain in Bengaluru; editing by Patrick Graham)
